Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.36
+0.06502.83%
Post-market: 2.400.0400+1.69%19:34 EDT
Volume:36.74K
Turnover:88.09K
Market Cap:23.54M
PE:-0.54
High:2.45
Open:2.30
Low:2.30
Close:2.30
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:0.56
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3700
EPS(LYR):-4.0377
ROE:-78.58%
ROA:-45.54%
PB:0.77
PE(LYR):-0.58

Loading ...

Atossa Therapeutics Announces AACR Poster Presentation on (z)-endoxifen in Mccune-albright Syndrome

Reuters
·
Jul 21

Atossa Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 08

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jul 07

Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront

Reuters
·
Jun 13

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 13

Top Midday Decliners

MT Newswires Live
·
Jun 12

Atossa Therapeutics Launches $16.5 Million Registered Direct Offering

MT Newswires Live
·
Jun 11

Atossa Therapeutics issues Series A and B warrants for 1,363,638 shares in registered direct offering at $3.3 each

Reuters
·
Jun 11

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 11

Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer

Reuters
·
May 27

Atossa Therapeutics Announces Asco 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across Esr1 Mutations and Ongoing Evangeline Phase 2 Trial

THOMSON REUTERS
·
May 27

Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication

Reuters
·
May 21

Atossa Therapeutics Inc expected to post a loss of $1.03 a share - Earnings Preview

Reuters
·
May 08

Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses

Reuters
·
May 08

Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models

Reuters
·
May 08

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million

Reuters
·
May 08

Atossa Therapeutics shareholders approve reverse stock split authorization

Reuters
·
May 08

Atossa says Phase 2 KARISMA trial shows Endoxifen cuts mammographic breast density 19.3%

Reuters
·
May 06